MCM
RIGL icon

Massar Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Massar Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,100
Closed -$314K – 366
2025
Q3 		$314K Buy
+11,100
New +$332K 0.04% 155

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Massar Capital Management's RIGL Position: Q4 2025 in Review

Massar Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2025, closing a stake of 11,100 shares — an estimated $314K sold.

Massar Capital Management first reported a position in RIGL in Q3 2025 and held it in 1 quarter. The position peaked at $314K in Q3 2025. 193 funds tracked by Wall St. Rank hold RIGL as of Q4 2025.

  • Massar Capital Management reported no remaining Rigel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Massar Capital Management sold 11,100 Rigel Pharmaceuticals shares in Q4 2025, an estimated $314K.
  • Massar Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Massar Capital Management's Rigel Pharmaceuticals position peaked at $314K in Q3 2025.
  • 193 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2025.

Based on Massar Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.